Drew Moghanaki/LinkedIn
Sep 9, 2025, 05:46
Drew Moghanaki: Unresectable Tumors Should Not Be Sent Down a Neoadjuvant Pathway at This Time
Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“I agree with Erin A Gillaspie that patients with unresectable tumors should not be sent down a neoadjuvant pathway at this time.
I also believe the legal risks are real and tough to defend in a court of law if a patient’s family chooses to sue a medical center for recommending such an approach.”
More posts featuring Drew Moghanaki.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 9, 2025, 05:35
Sep 9, 2025, 02:16
Sep 9, 2025, 02:03
Sep 9, 2025, 01:48
Sep 9, 2025, 01:43
Sep 9, 2025, 00:59
Sep 9, 2025, 00:46
Sep 8, 2025, 17:37